CN1296823A - Antineoplastic Chinese medicine and its preparing process - Google Patents
Antineoplastic Chinese medicine and its preparing process Download PDFInfo
- Publication number
- CN1296823A CN1296823A CN00107411A CN00107411A CN1296823A CN 1296823 A CN1296823 A CN 1296823A CN 00107411 A CN00107411 A CN 00107411A CN 00107411 A CN00107411 A CN 00107411A CN 1296823 A CN1296823 A CN 1296823A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- medicinal liquid
- medicine
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antineoplastic Chinese medicine for treating lung cancer, liver cancer, bone cancer and lymphosarcoma is prepared from 11 Chinese medicinal materials divided into 3 groups, including oldenlandia, subprostate sophora root, leech, centipede, white arsenic, etc. Its advantage is high curative effect.
Description
The present invention relates to a kind of antitumor drug and preparation technology thereof, relate in particular to a kind of pure Chinese medicine broad-spectrum anti-cancer drug preparation and preparation technology thereof.
The Therapeutic Method of all kinds of oncosises and the research of antitumor drug are that current medical circle is of greatest concern, also are to make progress one of the fastest field, and the treatment of malignant tumor is many at present by chemotherapy or X-ray therapy, cooperates relevant medicine auxiliary treatment simultaneously.The research of relevant Chinese medicine anti-tumor agent report is a lot of in recent years, but the most drug result of study all is to have certain specific aim, promptly only a certain or certain several tumor are worked, on treatment is used, a lot of limitation are arranged, particularly these medicine majorities are as the chemotherapy adjuvant, improper use can affect the treatment, even brings pair face result who is difficult to save to treatment.
The occupation mode of more present pure Chinese medicinal preparations, maximum still traditional decocting cooking method or decoction and alcohol sedimentation technique, the medicinal liquid that obtains directly uses or is processed into required dosage form, volatile part or water soluble ingredient then be difficult to keep in the active component of crude drug, that is to say that preparation after the processing may not comprise the whole active active ingredient in the crude drug.
The broad-spectrum anti-cancer drug that the purpose of this invention is to provide a kind of pure Chinese medicine adopts pure Chinese prescription preparation, and multiple cancerous cell is had inhibitory action, but and life-time service, have no side effect.
Another object of the present invention provides the preparation technology of said medicine, and the Chinese medicine method for making is combined with the modern science means, has farthest kept the effective ingredient in the crude drug.
The present invention also further provides the different dosage form of this medicine, for medicine for treatment provides multiple choices.
At first, the invention provides a kind of antitumor drug of pure Chinese prescription, active constituents of medicine wherein is from comprising following three groups raw material crude drug (in parts by weight):
A group: 10～30 parts of Herba Hedyotidis Diffusaes, 10～30 parts of Radix Sophorae Tonkinensiss, 1～10 part of Sargassum, 1～10 part of Thallus Laminariae (Thallus Eckloniae), 5～50 parts of Rhizoma Paridis, 1～30 part of the Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae);
B group: 1～20 part of Hirudo, 5～30 parts of Scolopendras, 1～10 part of Scorpio;
C group: 0.1～0.5 part of arsenicum, 0.1～0.6 part of Calomelas.
As a kind of pure Chinese medicine antitumor drug, the medicament composing prescription that the present invention proposes is determined through long-term test results, all inequality with the class Chinese prescription of the same race of report on the books and open, especially wherein the plant amedica Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae) of Cai Yonging has the expectorant of relieving oedema or abdominal distension through diuresis or purgation effect, drug effect value for liver, stomach, thyroid and digestive tract tumor will be higher than Folium et Ramulus Cephalotaxi, Herba Crotalariae sessiliflorae, the pharmaceutical research result is, with the Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae) lumbar injection suppression ratio of pulmonary carcinoma, hepatocarcinoma, cervical cancer reached 59.91～70.2%, 36.77% and 48.52% respectively; Rhizoma Paridis has heat-clearing and toxic substances removing and antineoplastic effect, digestive tract (esophagus, stomach etc.) tumor, pulmonary carcinoma, liver tumor, osteocarcinoma, lymphatic cancer and bladder cancer etc. there is the good restraining effect, as to the suppression ratio of murine sarcoma 40～50%, detect with the Cellular respiration method, Rhizoma Paridis reaches 85%～87% to the sarcoma of spleen suppression ratio that exsomatizes; Arsenicum and Calomelas use in the safety range amount, the treating the poisonous disease with poisonous drugs effect has been played in inhibition to malignant tumor especially, mainly show and kill active somatic cell, suppress leukocytic too much propagation, promote the generation of red blood cell proliferation and hematochrome, assimilation is strengthened, promote thickening and improving skin-nourishing of protein synthesis and fat, the acceleration skeleton is grown up, make the hemopoietic function of skeleton active, promote erythrocyte and hematochrome new life, theoretical and test all shows, these two kinds known hypertoxicity compatibility of drugss use, and can weaken its toxicity and be combined in to the harm of human body and with other medicines and have synergism in the treatment.The function of other crude drug in antitumor also gains public acceptance at Chinese medicine circle in the prescription.Feature of the present invention just is these antitumor crude drug are combined in specific prescription ratio, utilizes its synergism to obtain more ideal antitumor efficacy.
Pure Chinese medicine antitumor drug of the present invention can have different dosage forms such as the suppository, application of aqueous injection, oral liquid or oral tablet, oral capsule and external on dosage form, select to adopt according to disease, treatment needs and patient's state.
The present invention is a kind of pure Chinese medicine antitumor drug, and its preparation method can be traditional decocting cooking method, decoction and alcohol sedimentation technique, or other feasible methods.
According to another object of the present invention, the preparation technology of above-mentioned antineoplastic agent may further comprise the steps:
(1) A being organized listed raw material crude drug cleans with distilled water, the distilled water immersion 1～2 hour that adds 10～15 times of weight of this A group crude drug, look the amount of water situation and added thermal distillation 1.5～2.5 hours, collection and preservation distillate are stand-by, while filtration treatment surplus stock medicinal liquid, the medicinal liquid that leaches is also deposited separately, and the residual medicinal residues after will filtering carry out the distillation second time again, same operation, with the distillate of collecting and distillate merging for the first time, centrifugalize is carried out in medicinal liquid that leaches and the merging of primary medicinal liquid, gets the supernatant heating and concentrates back stand-by;
(2) B organizes listed raw material crude drug and cleans the back by traditional operation method adding distilled water immersion earlier 0.5～1 hour with distilled water, decocts then 1～2 hour, filters, medicinal residues are done for the second time with method and are decocted, and filter once more, twice medicinal liquid merges and carries out centrifugalize, gets after the supernatant concentration stand-by;
(3) arsenicum and the Calomelas with the C group places hermetic container, adds the medical ethanol extraction of its 500～1000 times of amounts, preserves 6～8 days down in 2～5 ℃;
(4) medicinal liquid with two groups of above-mentioned A, B merges, join in the extract of C group, preserved 10～20 hours down for 2～5 ℃, centrifugalize goes out supernatant, ethanol is reclaimed in distillation, and remaining medicinal liquid heating is concentrated into the total amount of raw materials used crude drug, adds solubilizing agent, carry out centrifugalize after preserving 10～20 hours under 2～5 ℃, the distillate of getting supernatant and step (1) merges.More than operation is all carried out under aseptic condition.
The medicinal liquid that obtains through above process, be the stock solution of broad-spectrum anti-cancer drug provided by the invention, preparation method can further be made the dosage form that needs routinely, as add solvent and make aqueous injection, add that syrup is made oral liquid or oral tablet, oral capsule etc. are made in corresponding dressing, can also make the suppository, application of external etc.
Wherein, used solubilizing agent can be any feasible solubilizing agent, its effect is the dissolubility that improves medicinal liquid, and to regulate its pH value be faintly acid to neutral, preferred solubilizing agent is a tween 85, tween 80 etc., and the use amount adding gets final product routinely, for example according to relevant standard, the addition of tween 85 is 0.5～1%.
According to preparation technology of the present invention, for guaranteeing effective treatment, in the operation of (4) step, requirement is concentrated into medicinal liquid the total amount of raw materials used crude drug, but not absolute in practical operation, if the amount of water when handle early stage is less, might concentrate less than the amount that requires, can replenish this moment with the part distillate.
According to preparation technology of the present invention as can be seen, its characteristics are different types of crude drug is adopted earlier different disposal respectively, and promptly the animal material medicine to the B group adopts traditional decocting method, collects medicinal liquid; Mineral medicine material organic solvent extractionprocess to the C group; Botanical herbs to the A group then adopts way of distillation recovery volatile component wherein earlier, at last again add back in medicinal liquid as pharmaceutical diluents it, simultaneously wherein not volatile aqueous soluble active constituent is gone out to obtain water and carries medicinal liquid by water-soluble in heating process, its effect is that the two combination makes the effective active components of crude drug obtain the full use of maximum possible, thereby has increased drug effect; In addition, the present invention adopts the distillate of plant amedica itself as diluent, no longer adds and use other diluent, makes the drug effect level of the more approaching original prescription of effective ingredient in the medicine of the present invention, and drug effect increases and has no side effect.
In a word, the purpose of this invention is to provide a kind of broad spectrum anticancer new drug that adopts pure Chinese prescription to make, except that the above-mentioned Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae) and Rhizoma Paridis, Herba Hedyotidis Diffusae in its prescription, Scorpio, Radix Sophorae Tonkinensis, having of Scolopendra tumor, anticancer, removing food stagnancy and Detoxication, Sargassum, Thallus Laminariae (Thallus Eckloniae), Hirudo have the effect of blood circulation promoting and blood stasis dispelling, the diffusing joint effect of softening the hard mass, be equipped with the special role of arsenicum and Calomelas, drug effect and pharmacological testing show that all medicine of the present invention has the increase body immune function; Suppress and tumoricidal growth, division and propagation, finally cause cancer cellular necrosis; Can quicken skeleton to the osteocarcinoma patient generates, excite and improve the hemopoietic function of skeleton, by promoting the new characteristics of resisting the existence of cancerous cell from birth of erythrocyte and hematochrome, particularly ought be used for the radiation and chemotherapy patient, can alleviate because the caused toxic and side effects of radiation and chemotherapy has anticancer, cancer suppressing action under the situation of not damaging human normal cell's tissue.Prove that through pharmacology and effect experiment medicine of the present invention is all effective in cure to pulmonary carcinoma, hepatocarcinoma, gastric cancer, cancer of pancreas, colon cancer, rectal cancer, bladder cancer, uterus carcinoma, breast carcinoma, cerebroma and nasopharyngeal carcinoma, lymphosarcoma etc.
Accompanying drawing 1 is the process chart of the present invention from crude drug to medicine stock solution.
After medicine stoste is made, can make the antineoplastic system of various formulations by the routine operation method Agent, as allocate solvent or water for injection, physiological saline etc. into, make liquid drugs injection; Add syrup, make mouth Take the liquor type; Allocate filler and auxiliary material into, can be made into tablet or capsule by compressing tablet or dress capsule.
Use the animal acute toxicity test result of mouse, medicine of the present invention is through the half lethal dose LD of intravenously administrable50Be 2.448g/kg, its 95% average credible 2.4448 ± 0.253g/kg that is limited to; Through half of stomach administration Lethal dose LD50Be 6.04g/kg, its 95% average credible 6.04 ± 0.98g/kg that is limited to.
The inventor has also carried out local excitation experiment and hemolytic experiment, assay, no blood with it rabbit The IRs such as swollen, hyperemia also do not have haemolysis in regulation and take place in observing time.
Be that proof medicine of the present invention in the effect of anti-tumor aspect, makes medication stoste: water for injection is 1: 1 Parenteral solution is according to " screening rules (draft) in the national antineoplastic animal body are respectively to sarcoma 180 (S180), EC (EAC), liver cancer (HepA) and leukemic lymphoblastoid (L1210) etc. Animal tumor has carried out the effect experiment of anti-animal tumor. Experiment is to select same sex, and body weight exists 18～22g, healthy kunming mice or pure lines DDA, C57 mouse, random packet is carried out. By following formula Calculate tumour inhibiting rate:
" rules " require when tumour inhibiting rate＞30%, and there were significant differences (p＜0.05) to learn by statistics processing, Repeat 3 times continuously, the result is stable, and it is effective in cure to this tumour then to be assessed as experimental drug.
1, to the inhibitory action statistics of S180, under aseptic condition, give experiment mice right fore armpit subcutaneous (it is thin to contain approximately 5,000,000 unit S180 cancers for the S180 cancer cell nutrient solution 0.2m1 that inoculation is disinfected in advance Born of the same parents), the random packet numbering, each 10 of experimental group and control groups, mouse average weight difference is little between every group In 1.0g. Inoculate next day, experimental group lumbar injection the invention described above parenteral solution 0.21ml, control group The physiological saline of injection same amount, be administered once every day, successive administration 7 days. Last administration time Day is put to death animal, takes out the cancer piece and weighs, and calculates tumour inhibiting rate.
Table 1 medicine of the present invention is to the inhibitory action of S180
| Object | Number of animals | Average the weight of animals | Average knurl heavy (gram) | Tumour inhibiting rate % | p |
| Beginning/finish | Beginning/finish (gram) | ||||
| Experimental group 1 | 10/10 | 19.9/24.6 | 1.84 | 45.9％ | ＜0.001 |
| Control group 1 | 10/9 | 19.8/23.4 | 3.40 | ||
| Experimental group 2 | 10/10 | 20.0/23.4 | 2.11 | 37.9％ | ＜0.001 |
| Control group 2 | 10/9 | 19.8/23.4 | 3.40 | ||
| Experimental group 3 | 10/10 | 19.9/24.9 | 0.60 | 47.8％ | ＜0.005 |
| Control group 3 | 10/10 | 19.5/23.9 | 1.15 |
2, to the effect of HepA, give mouse right fore armpit subcutaneous vaccination HepA ascites 0.2ml (HepA Amount is 2,500 ten thousand/ml), is divided at random experimental group and control group after the inoculation, mouse average body between each group The method of double differences is different from 1.0g, inoculates rear 24 hours beginning experimental group intraperitoneal administrations, control group injection same amount Physiological saline, be administered once every day, successive administration 7 days. Put to death animal the next day of last administration, Take out the cancer piece and weigh, calculate tumour inhibiting rate.
Table 2 medicine of the present invention is to the inhibitory action of HepA
| Object | Number of animals | Average the weight of animals | Average knurl heavy (gram) | Tumour inhibiting rate % | p |
| Beginning/finish | Beginning/finish (gram) | ||||
| Experimental group 1 | 10/10 | 19.0/21.8 | 0.66 | 45.9％ | ＜0.05 |
| Control group 1 | 10/10 | 19.3/21.7 | 1.22 | ||
| Experimental group 2 | 10/10 | 20.5/20.8 | 0.58 | 51.3％ | ＜0.001 |
| Control group 2 | 10/10 | 20.3/20.6 | 1.19 | ||
| Experimental group 3 | 10/10 | 18.5/19.1 | 0.48 | 50.1％ | ＜0.05 |
| Control group 3 | 10/10 | 18.5/19.1 | 0.97 |
3, to the effect of EAC, give mouse right fore armpit subcutaneous vaccination EAC ascites 0.2ml (EAC Amount is 2,500 ten thousand/ml), is divided at random each 10 of experimental group and control groups after the inoculation, mouse between each group Average weight difference is inoculated rear 24 hours beginning experimental group intraperitoneal administrations, the control group injection less than 1.0g The physiological saline of same amount, be administered once every day, successive administration 7 days. Place's next day of last administration Dead animal is taken out the cancer piece and weighs, and calculates tumour inhibiting rate. Table 3, medicine of the present invention is to the inhibitory action of EAC
| Object | Number of animals | Average the weight of animals | Average knurl heavy (gram) | Tumour inhibiting rate % | p |
| Beginning/finish | Beginning/finish (gram) | ||||
| Experimental group 1 | 10/10 | 20.3/24.7 | 0.83 | 39.9％ | ＜0.05 |
| Control group 1 | 10/10 | 20.1/24.3 | 1.38 | ||
| Experimental group 2 | 10/10 | 20.4/25.1 | 0.87 | 37.0％ | ＜0.05 |
| Control group 2 | 10/10 | 20.1/24.3 | 1.38 |
Test statistics is the result show, medicine of the present invention has stable and significant treatment to multiple mouse tumor Effect: the average tumour inhibiting rate to S180 is 43.9%, SE ± 5.3, p＜0.005～0.001; To HepA Average tumour inhibiting rate 49.1%, SE ± 2.8, p＜0.05～0.001; Average tumour inhibiting rate to EAC is 38.5%, SE ± 2.1, p＜0.05 did not occur toxic and side effect in continuous 7～9 days with same test dose simultaneously, the experiment knot Fruit is stable, can think that medicine of the present invention is effective in cure to the treatment of above-mentioned tumour.
Embodiment 1
The crude drug prescription:
A group: Herba Hedyotidis Diffusae 150 grams, Radix Sophorae Tonkinensis 150 grams, Sargassum 30 grams, Thallus Laminariae (Thallus Eckloniae) 30 grams, Rhizoma Paridis 205 grams, the Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae) 150 grams;
B group: Hirudo 100 grams, Scolopendra 150 grams, Scorpio 30 grams;
C group: arsenicum 2 grams, Calomelas 3 grams.
Aqueous injection preparation technology:
(1) A being organized listed raw material crude drug cleans with distilled water, put into alembic and add the about 10000ml immersion of distilled water 1 hour, added thermal distillation 2 hours (look the water yield and can prolong or shorten distillation time slightly), collection and preservation distillate are stand-by, while filtration treatment surplus stock medicinal liquid, the medicinal liquid that leaches is also deposited separately, and the residual medicinal residues after will filtering are put back to and are carried out second time distillation in the alembic, same operation, with the distillate of collecting and distillate merging for the first time, centrifugalize is carried out in medicinal liquid that leaches and the merging of primary medicinal liquid, gets the supernatant heating and concentrates back stand-by;
(2) B organizes listed raw material crude drug and cleans the back by traditional operation method adding 3000ml distilled water immersion earlier 1 hour with distilled water, decocts then 2 hours, filters, medicinal residues are done for the second time with method and are decocted, and filter once more, twice medicinal liquid merges and carries out centrifugalize, gets after the supernatant concentration stand-by;
(3) arsenicum and the Calomelas with the C group places hermetic container, adds the medical ethanol extraction of 3000ml 95%, and preservation is stand-by after 7 days down in 4 ℃ to put into refrigerator;
(4) medicinal liquid with two groups of above-mentioned A, B merges, join in the extract of C group, preserved 12 hours down for 4 ℃, centrifugalize goes out supernatant, ethanol is reclaimed in distillation, the heating of the medicinal liquid that stays is concentrated into about 1000 grams, adds 1% tween 85, and dissolving is placed on preserved 12 hours in 4 ℃ of refrigerators or spend the night, carry out centrifugalize, get supernatant buchner funnel sucking filtration, the distillate merging with filtrate and step (1) becomes medicine stock solution.More than operation is all carried out under aseptic condition.
(5) above-mentioned medicine stock solution was sneaked into 0.9% normal saline by 1: 1, added 0.5% tween 85 again, and heating for dissolving is even and adjust its pH to 4～7, makes medicinal liquid be transparence, sterilizes behind the filling bottle, becomes aqueous injection.
Every 2ml of this injection, usage and consumption: each 1～2, every day secondary, intramuscular injection.
In (5), medicine stock solution is made oral liquid by oral liquid technology, every 10ml, oral each 1～2, every day secondary.
Claims (6)
1, a kind of antitumor drug, active constituents of medicine wherein be from comprising following three groups raw material crude drug, in parts by weight:
A group: 10～30 parts of Herba Hedyotidis Diffusaes, 10～30 parts of Radix Sophorae Tonkinensiss, 1～10 part of Sargassum, 1～10 part of Thallus Laminariae (Thallus Eckloniae), 5～50 parts of Rhizoma Paridis, 1～30 part of the Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae);
B group: 1～20 part of Hirudo, 5～30 parts of Scolopendras, 1～10 part of Scorpio;
C group: 0.1～0.5 part of arsenicum, 0.1～0.6 part of Calomelas.
2, the described antitumor drug of claim 1, active constituents of medicine wherein be from comprising following three groups raw material crude drug, in parts by weight:
A group: 15 parts of Herba Hedyotidis Diffusaes, 15 parts of Radix Sophorae Tonkinensiss, 3 parts of Sargassums, 3 parts of Thallus Laminariae (Thallus Eckloniae)s, 20.5 parts of Rhizoma Paridis, 15 parts of the Radixs Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae);
B group: 10 parts of Hirudos, 15 parts of Scolopendras, 3 parts of Scorpios;
C group: 0.2 part of arsenicum, 0.3 part of Calomelas.
3, claim 1 or 2 described antitumor drug, it comprises suppository, the application dosage form of aqueous injection, oral liquid or oral tablet, oral capsule or external.
4, a kind of preparing anti-tumor medicine technology, raw material crude drug comprise following three groups in weight portion:
A group: 10～30 parts of Herba Hedyotidis Diffusaes, 10～30 parts of Radix Sophorae Tonkinensiss, 1～10 part of Sargassum, 1～10 part of Thallus Laminariae (Thallus Eckloniae), 5～50 parts of Rhizoma Paridis, 1～30 part of the Radix Euphorbiae Fischerianae (Radix Euphorbiae Ebracteolatae);
B group: 1～20 part of Hirudo, 5～30 parts of Scolopendras, 1～10 part of Scorpio;
C group: 0.1～0.5 part of arsenicum, 0.1～0.6 part of Calomelas;
Preparation technology may further comprise the steps:
(1) A being organized listed raw material crude drug cleans with distilled water, the distilled water immersion 1～2 hour that adds 10～15 times of weight of this crude drug, distilled 1.5～2.5 hours, collection and preservation distillate are stand-by, filtration treatment surplus stock medicinal liquid, the medicinal liquid that leaches is also deposited separately, and the residual medicinal residues after will filtering carry out the distillation second time again, same operation, with the distillate and distillate merging for the first time that obtains, centrifugalize is carried out in medicinal liquid that leaches and the merging of primary medicinal liquid, gets the supernatant heating and concentrates back stand-by;
(2) B organizes listed raw material crude drug and cleans the back by traditional operation method adding distilled water immersion earlier 0.5～1 hour with distilled water, decocts then 1～2 hour, filters, medicinal residues are done for the second time with method and are decocted, and filter once more, twice medicinal liquid merges and carries out centrifugalize, gets after the supernatant concentration stand-by;
(3) arsenicum and the Calomelas with the C group places hermetic container, adds the medical ethanol extraction of its 500～1000 times of amounts, preserves 6～8 days down in 2～5 ℃;
(4) medicinal liquid with two groups of above-mentioned A, B merges, join in the extract of C group, preserved 10～20 hours down for 2～5 ℃, centrifugalize goes out supernatant, and ethanol is reclaimed in distillation, and remaining medicinal liquid heating is concentrated into the total amount of used all raw material crude drugs, add solubilizing agent, carry out centrifugalize after preserving 10～20 hours under 2～5 ℃, the distillate of getting supernatant and step (1) merges, and becomes medicine stock solution.
5, the described preparation technology of claim 4, wherein, used solubilizing agent is a tween 85, conventional use amount adds.
6, claim 4 or 5 described preparation technologies, it also comprises: sneaked into 0.9% normal saline by 1: 1 in medicine stock solution, and add the tween 85 of solution amount 0.5%, heating for dissolving is made aqueous injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00107411A CN1106199C (en) | 2000-05-09 | 2000-05-09 | Antineoplastic Chinese medicine and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00107411A CN1106199C (en) | 2000-05-09 | 2000-05-09 | Antineoplastic Chinese medicine and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1296823A true CN1296823A (en) | 2001-05-30 |
| CN1106199C CN1106199C (en) | 2003-04-23 |
Family
ID=4578684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00107411A Expired - Fee Related CN1106199C (en) | 2000-05-09 | 2000-05-09 | Antineoplastic Chinese medicine and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1106199C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318040C (en) * | 2004-06-29 | 2007-05-30 | 龙良云 | Method for producing medicine egg for treating child lymph tuberculosis |
| CN1970034B (en) * | 2006-12-05 | 2011-09-07 | 北京天力正元医药技术开发有限公司 | Chinese medicine containing gadol and tuckahoe |
| CN101524465B (en) * | 2009-03-19 | 2012-05-30 | 陈震 | External dipping medicine for remedying cancer |
| CN103977257A (en) * | 2014-05-23 | 2014-08-13 | 李绍益 | Medicinal composition for treating lung cancer |
-
2000
- 2000-05-09 CN CN00107411A patent/CN1106199C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318040C (en) * | 2004-06-29 | 2007-05-30 | 龙良云 | Method for producing medicine egg for treating child lymph tuberculosis |
| CN1970034B (en) * | 2006-12-05 | 2011-09-07 | 北京天力正元医药技术开发有限公司 | Chinese medicine containing gadol and tuckahoe |
| CN101524465B (en) * | 2009-03-19 | 2012-05-30 | 陈震 | External dipping medicine for remedying cancer |
| CN103977257A (en) * | 2014-05-23 | 2014-08-13 | 李绍益 | Medicinal composition for treating lung cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1106199C (en) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN101020719B (en) | Composite angelica polysaccharide and its preparation process and use | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN100586450C (en) | Phenolic extract of duchesnea indica focke, preparation method and application thereof | |
| CN1106199C (en) | Antineoplastic Chinese medicine and its preparing process | |
| CN104857435A (en) | Chinese herbal compound composition with antineoplastic activity as well as preparation method and application thereof | |
| CN1939396A (en) | Suberect spatholobus stem extract with antineoplastic function and its making method | |
| CN1284599C (en) | Medicine for treating tumor and its preparation process | |
| CN102225089B (en) | Pharmaceutical composition for treating cancers, pharmaceutical preparation as well as applications and production methods thereof | |
| CN1131029C (en) | Composite medicine containing dihydromyricetrin | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN104825783B (en) | Chinese medicine composition with antitumor activity and its preparation method and application | |
| CN1094357C (en) | Anticancer oral liquid and its preparation method | |
| CN105012366B (en) | A kind of bright moon grass polysaccharide and its application in preparing for immunological regulation and anti-tumor drug and functional food | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN1083725C (en) | Cordyceps medicinal composition and its preparing method | |
| CN1834108B (en) | Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN1279928C (en) | Extracts and use of Leimo | |
| CN1836674A (en) | Antler lucid ganoderma and its extract for preparing pharmaceutical and food for treating cancer and immunity effect | |
| CN101401820B (en) | Injection novel medicine for treating systematic lupus erythematosus | |
| CN1265808C (en) | Combination of medication for anti herpes virus and its application | |
| CN1122523C (en) | Medicine for curing malignant tumor and its preparation method | |
| CN1267095C (en) | Application use of dihydromyricetrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG LILI; ZHAO SHU Free format text: FORMER OWNER: ZHANG LILI Effective date: 20011019 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20011019 Address after: 4, Qingming District, Nangang District, Heilongjiang, Harbin 1-1 Applicant after: Zhang Lili Applicant after: Zhao Shu Address before: 4, Qingming District, Nangang District, Heilongjiang, Harbin 1-1 Applicant before: Zhang Lili |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |